Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat with Umbralisib and Ublituximab in R/R Follicular Lymphoma
NCT05152459Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in follicular lymphoma (FL), sponsored by City of Hope. Primary endpoints: Dose-limiting toxicity at 28 days and Overall response rate at 2 years. Planned start May 2023; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05152459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152459.